Next-Generation Biologics Market Size, Share, and Forecast (2025–2032)

According to Global Data Stats, The global Next-Generation Biologics Market size accounted for USD 110.52 Billion in 2024 and is predicted to increase from USD 122.21 Billion in 2025 to approximately USD 246.48 Billion by 2032, expanding at a CAGR of 8.54% from 2025 to 2032.

The Next-Generation Biologics Market Report offers a comprehensive evaluation of the current market scenario and its future prospects. It discusses in detail the main growth drivers, current trends, challenges, and business opportunities. Additionally, it presents insights on market segmentation, major competitors, and future forecasts, helping businesses prepare actionable growth strategies for the coming years.

Scope of the Report

This study provides a complete analytical view of the Global Next-Generation Biologics Market, prepared using secondary data research, primary discussions with industry experts, and in-house validation. The estimates take into account the social, political, and economic factors shaping the industry, together with dynamic changes within the market environment.

The analysis also features a Porter’s Five Forces framework, which examines the negotiating power of buyers and suppliers, barriers for new entrants, risk of substitutes, and competition intensity to provide clarity on the overall market ecosystem. Furthermore, the report focuses on the role of key stakeholders — system integrators, intermediaries, and end-users — to evaluate how they influence the industry.

Competitive Landscape

The competitive scenario of the Global Next-Generation Biologics Market consists of multiple important players, from large established corporations to emerging startups. To strengthen their position, companies are concentrating on innovation, partnerships, acquisitions, and entry to new markets. This competition fosters technological advancement and forces businesses to enhance their portfolios and strategies.

Report Coverage:

Overview of the Next-Generation Biologics Market

The report presents an in-depth overview of the Next-Generation Biologics Market, highlighting the drivers, restraints, and opportunities influencing growth. It provides accurate revenue data, market forecasts, and share analysis of key firms, giving a clear understanding of how leading companies perform globally. The overview also emphasizes regional demand, customer needs, and future requirements, giving readers a precise perspective of both market supply and demand side.

Report Highlights

The report highlights several core aspects, such as a full analysis of market factors, the present market environment, and reliable future projections. It combines global and regional perspectives, supported by country-level insights. Detailed classification of market participants also ensures businesses can identify key players in every geography, while understanding local demand patterns and wider industry needs.

Key Players:

The report lists and analyzes leading companies involved in the Global Next-Generation Biologics Market. These key players are studied in terms of market contribution, strategies, competitive strengths, and business performance. Both top global firms and rising market participants are included, showing how competition takes shape across industries and geographies.

• Roche Holding AG

• Amgen Inc.

• Johnson & Johnson (Janssen Biotech)

• Bristol-Myers Squibb (BMS)

• Pfizer Inc.

• Novartis AG

• Merck & Co., Inc.

• AbbVie Inc.

• Gilead Sciences, Inc.

• Sanofi S.A.

• AstraZeneca plc

• Takeda Pharmaceutical Co. Ltd.

• Regeneron Pharmaceuticals

• Biogen Inc.

• UCB S.A.

• Alnylam Pharmaceuticals

• Moderna, Inc.

• BioNTech SE

• Bluebird Bio

• Sangamo Therapeutics

Market Segmentation

The Global Next-Generation Biologics Market is segmented by product type, application, and end-use industries. Each segment has been examined in detail to underline its contribution to revenue generation, growth enhancement, and challenges faced. Such segmentation helps businesses identify priority markets and investment areas.

Along with segmentation, the study explains performance across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Each region’s consumer preferences, industrial potential, and barriers to entry are considered. Additionally, a PEST analysis (Political, Economic, Social, and Technological factors) is included for major regions, presenting a clear picture of local influences shaping the industry.

The research provides forecast data from 2025 to 2032, explaining CAGR percentages, USD values, and market variations, supported with reliable insights from analysts and industry professionals.

Segments Covered in the Report

By Product Type

• Antibody Drug Conjugates (ADCs) 
• Bispecific Antibodies 
• Fusion Protein Therapeutics 
• Monoclonal Antibody Fragments (e.g., Fab, scFv) 
• Engineered Cytokines 
• Cell-Based Therapies (e.g., CAR-T) 
• Gene Therapies 
• RNA-Based Biologics (e.g., siRNA, mRNA) 
• Nanobodies & Single-Domain Antibodies 
• Others (e.g., Protein Scaffolds, Aptamers) 

By Disease Area

• Oncology 
• Autoimmune & Inflammatory Disorders 
• Genetic Disorders (e.g., hemophilia, SMA) 
• Infectious Diseases (e.g., HIV, COVID-19) 
• Ophthalmic Diseases (e.g., AMD) 
• Neurological Disorders 
• Others (e.g., metabolic, cardiovascular) 

By Manufacturing Platform

• Mammalian Cell Culture (CHO, HEK293) 
• Microbial Systems (E. coli, Yeast) 
• Cell-Free Expression Systems
• Viral Vectors (Lentivirus, AAV) 
• RNA Synthesis Platforms 
• Others (e.g., Plant-based, Insect cell systems) 

By Route of Administration

• Intravenous (IV) 
• Subcutaneous (SC) 
• Intramuscular (IM) 
• Intrathecal/Intraocular 
• Others (e.g., Inhalation, Topical) 

By Distribution Channel

• Hospital Pharmacies 
• Specialty Pharmacies 
• Retail Pharmacies 
• Others (e.g., Direct-to-Patient, Clinical Sites) 

By Region

• North America 
• Europe 
• Asia Pacific 
• Latin America 
• Middle East & Africa

Our team of dedicated analysts, research specialists, and skilled forecasters carefully prepare this market report. It clearly presents the market data in terms of USD values and CAGR (compound annual growth rate), along with their expected changes for the given forecast period.

Regional Analysis for Next-Generation Biologics Market

• North America (the United States, Canada, and Mexico)
  
  
• Europe (Germany, France, UK, Russia, and Italy)
  
  
• Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
  
  
• South America (Brazil, Argentina, Colombia, etc.)
  
  
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa).

Objectives of the Study

The main objective of this research is to analyze the current market in detail and predict future growth prospects. The study seeks to define and assess the industry structure by identifying sub-segments and their contributions. It also evaluates market value, global share, SWOT analysis of key companies, and overall competition while highlighting opportunities for investment and innovation.

Insights Before Purchase

The report provides detailed participant analysis, allowing businesses to observe the competitive position of players. By offering insights into strategies being used, companies can design policies, re-adjust target markets, and identify growth-focused areas before investing.

Regional Analysis

The report studies five major regions in detail:

North America continues to lead due to its innovation, advanced technological infrastructure, and supportive government policies. Sectors such as healthcare, automotive, and technology, etc., are key demand areas. The United States and Canada remain the largest markets in this region.

Europe is a major contributor, driven by its sustainability goals, environmental policies, and deep industrial base. Countries including Germany, the UK, and France remain ahead by adopting new industry practices and supporting green solutions under strict regulations. 

Asia-Pacific is projected to post the highest growth rate during 2025–2032. Rapid urbanization, industrial growth, infrastructure expansion, economic development, and a growing middle class collectively fuel the demand here. Countries like China, India, and Japan are key drivers of demand.

Latin America has strong potential, particularly in Brazil, Mexico, and Argentina, where governments are supporting industrial diversification and technology adoption. This makes the region favorable for future market investment.

Middle East & Africa are emerging as essential markets, helped by infrastructure programs, increased industrialization, and diversification strategies. The UAE, Saudi Arabia, and South Africa account for the largest growth share in this region. 

The sample pages for this report are readily available on demand.

Recent Developments

• June 2025 – Zydus Lifesciences announced its entry into the global biologics CDMO sector by acquiring Agenus's biologics manufacturing facilities in California.

  • This strengthens Zydus's presence in the CDMO market.

  • The company will also act as the exclusive contract manufacturer for Agenus’s advanced immuno-oncology products Botensilimab and Balstilimab.

• May 2025 – Biocon Biologics Ltd. introduced access agreements for Yesintek™ (ustekinumab-kfce), its biosimilar of Stelara®.

  • The agreements cover over 100 million lives in the United States.

  • Major payers such as Express Scripts, Cigna, UnitedHealthcare, CVS Health, and Optum Rx have included it in their formularies.

  • CEO Shreehas Tambe described this launch as a significant milestone, ensuring affordable treatments for patients.

• February 2025 – BioNTech SE acquired Biotheus, a clinical-stage biotechnology company.

  • Biotheus specializes in novel antibodies for oncology and inflammatory diseases.

  • The acquisition followed their work on a bispecific antibody targeting PD-L1 and VEGF-A.

  • The deal was worth $800 million in cash and stock, with additional performance payments of up to $150 million.

• September 2024 – Temple OrthoBiologics, a spin-off of Temple Therapeutics, was launched on International Arthrofibrosis Awareness Day.

  • The company is focused on treating knee and joint injuries caused by scar tissue in sports medicine.

  • Its R&D center is in Liège with global collaborations in the USA, Canada, the UK, and the Netherlands.

  • Co-Founder Dr. Riley J. Williams III, an orthopedic surgeon and athlete, emphasized the potential of their new therapy TX-33 to transform sports injury care.

• April 2024 – The FDA introduced the Biosimilars Action Plan (BAP).

  • The plan aims to simplify development and approval of biosimilars.

  • It focuses on improving regulatory clarity, educating stakeholders, and supporting biosimilar adoption.

  • The main objective is to boost innovation, enhance competition, and encourage the use of biosimilars and interchangeable biosimilars.

Research Methodology

The report relies on a three-tier methodology:

• Primary research included direct interviews via phone, emails, and personal discussions with industry experts and decision-makers worldwide. This ensured unbiased, real-time insights on market trends, growth, and challenges.
  
  
• Secondary research was conducted through company financial reports, industry journals, government publications, and recognized databases to verify findings and create strong historical context.
  
  
• Data triangulation was applied to cross-check figures from various sources, ensuring consistency and eliminating discrepancies.

For forecasting, advanced statistical models such as regression analysis, time-series evaluation, and econometric methods were used. This helped create highly accurate market predictions until 2032.

Key Questions Addressed

The report provides answers to key questions such as:

• How has the global Next-Generation Biologics Market performed so far, and what is its forecast for the coming years?
  
  
• What are the chief drivers and challenges influencing growth?
  
  
• How is the market broken down by product type and application?
  
  
• Which regions and countries represent leading or fast-growing markets?
  
  
• Who are the key competitors, and what strategies do they use?
  
  
• What has been the impact of COVID-19 on the market’s growth?
  
  
• What stages of growth strategies are visible within the industry?
  
  
• What is the degree of competition across different regions?
  
  
• How are Next-Generation Biologics Market products manufactured and distributed?

Reasons to Purchase this Report

• Provides a 360-degree view of the market with both qualitative and quantitative insights.
  
  
• Explains the influence of economic and non-economic factors on market growth.
  
  
• Assesses the impact of major global events such as:
  
  
• Political conflicts
  
  
• Pandemic and recovery cycles
  
  
• Inflation trends
  
  
• Interest rate changes
  
  
• Governance shifts (e.g., 2nd Trump presidency)
  
  
• Offers USD values and volume analysis for every segment and sub-segment.
  
  
• Enables creation of regional and country-level strategies.
  
  
• Identifies high-growth investment areas and opportunities.
  
  
• Provides forecasted data to help businesses stay ahead of competitors.
  
  
• Allows performance benchmarking against industry leaders.
  
  
• Includes detailed company profiles with:
  
  
• SWOT analysis
  
  
• Product portfolios
  
  
• Benchmarking comparisons
  
  
• Market rankings
  
  
• Provides insights into M&A activities, partnerships, and business expansions in the last five years.
  
  
• Covers both current and future market outlooks, bridging opportunities across emerging and developed markets.
  
  
• Features strategic tools including Porter’s Five Forces Analysis, Value Chain assessments, and market dynamics evaluation.
  
  
• Comes with six months of post-sales analyst support to offer ongoing expert guidance. 

Frequently Asked Questions

1. What does this Next-Generation Biologics Market report cover?
   
   This Next-Generation Biologics Market report analyzes the main factors that drive market growth while presenting a clear picture of the competitive landscape. It explains the role of different market segments and applications that may impact future industry performance. Based on current trends and historical data, it includes detailed segmentation, regional insights, and competitive analysis.
   
   
2. Does the Next-Generation Biologics Market report estimate the current market size?
   
   Yes. The Next-Generation Biologics Market report evaluates the current size of the industry and offers reliable forecasts. The Next-Generation Biologics Market was valued at USD 122.21 Billion in 2025 and is predicted to grow at a CAGR of 8.54% between 2025 and 2032.
   
   
3. Does the Next-Generation Biologics Market report provide market size in both value and volume?
   
   Yes. The analysis covers the market not only in terms of Value (USD Million/Billion) but also in Volume (thousand tons, metric tons, cubic meters, etc.).
   
   
4. What are the main segments studied in Next-Generation Biologics Market report?
   
   The Next-Generation Biologics Market is divided into Product Types, Applications, End-users, and Regions.
   
   
5. Which Next-Generation Biologics Market dynamics are covered?
   
   The study covers market size, forecasts, opportunities, drivers, restraints, regulatory frameworks, emerging trends, PESTLE analysis, Porter’s Five Forces, pricing, trade flows, export-import analysis, product approvals, and promotional strategies. It helps businesses in making well-informed investment decisions.
   
   
6. Does Next-Generation Biologics Market report offer customization?
   
   Yes. Global Data Stats offers full customization options, allowing organizations to tailor the report for specific regions, countries, or market segments of interest. This ensures the data aligns with each company’s needs and strategic goals.